Last reviewed · How we verify
Paclical®
Paclical is a formulation of paclitaxel, a microtubule inhibitor that disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells.
Paclical is a formulation of paclitaxel, a microtubule inhibitor that disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis in cancer cells. Used for Non-small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | Paclical® |
|---|---|
| Sponsor | Oasmia Pharmaceutical AB |
| Drug class | Taxane |
| Target | Microtubules |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Paclitaxel works by binding to tubulin and stabilizing microtubules, preventing their disassembly and thereby inhibiting cell division. This leads to cell cycle arrest and ultimately apoptosis in rapidly dividing cancer cells. The formulation of paclitaxel in Paclical is designed to improve its solubility and delivery to cancer cells.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
Common side effects
- Neutropenia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Paclical® CI brief — competitive landscape report
- Paclical® updates RSS · CI watch RSS
- Oasmia Pharmaceutical AB portfolio CI